Azadeh Kiumarsi

Azadeh Kiumarsi


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2024 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
TRTahereh Rostami
Tahereh Rostami
MRMohammad Reza Rostami
Mohammad Reza Rostami
AMAmir Hossein Mirhosseini
Amir Hossein Mirhosseini
SMSaeed Mohammadi
Saeed Mohammadi
MNMohsen Nikbakht
Mohsen Nikbakht
AKAmir Kasaeian
Amir Kasaeian
Background: Graft failure (GF) is a rare but serious complication after allogeneic hematopoietic stem cell transplantation (HSCT). Prevention of graft failure remains the most advisable approach as there is no clear recommendation for the best strategies for reversing this complication. Administration of growth factor, additional hematopoietic progenitor boost, or a salvage HSCT are current modalities recommended for the treatment of GF. Autologous recovery without evidence of disease relapse occurs rarely in patients with GF, and in the absence of autologous recovery, further salvage transplantation following a second conditioning regimen is a potential treatment option that offers the best chances of long-term disease-free survival. The preconditioning regimens of second HSCT have a significant impact on engraftment and outcome, however, currently there is no consensus on optimal conditioning regimen for second HSCT in patients who have developed GF. Furthermore, a second transplant from a different donor or the same donor is still a matter of debate. Observations: We present our experience in managing pediatric patients with acute leukemia who encountered graft failure following stem cell transplantation. Conclusions and relevance: Although a second transplantation is almost the only salvage method, we illustrate that some pediatric patients with acute leukemia who experience graft failure after an allogeneic stem cell transplant using Myeloablative conditioning (MAC) regimen may achieve long-term disease-free survival through autologous hematopoiesis recovery.


7 March 2020 in Fertility Research and Practice
Verified
Journal Article
Open access
PDF file
TRTahereh Rostami
Tahereh Rostami
MMMohammad Amir Mohammadifard
Mohammad Amir Mohammadifard
SAShahla Ansari
Shahla Ansari
AKAzadeh Kiumarsi
Azadeh Kiumarsi
NMNasrollah Maleki
Nasrollah Maleki
AGArdeshir Ghavamzadeh
Ardeshir Ghavamzadeh
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative treatment for thalassemia major (TM). Infertility and its indicators have been assessed in transfusion dependent TM men, but in this study, we sought to compare the fertility indicators of TM patients after HSCT with those in patients treated conventionally. The possible influential factors on reproductive capacity in TM patients undergone allogeneic HSCT were also evaluated. Patients and methods: In this cross-sectional study, we compared the gonadal hormones level, testicular volume, Tanner stage and sperm analysis in transfusion-dependent thalassemia major (TDTM) patients who survived matched sibling HSCT (n = 43) with patients conventionally treated by transfusion and iron chelation (n = 52). Results: The patients’ age range was between 16 to 41 years. Tanner stage 4–5 was seen in 39 patients (41%). The prevalence of hypogonadism in our patients was 32.63% but its frequency was not significantly different between the two groups (p = 0.35). Azospermia, oligospermia, astenospermia, teratospermia and even having dry and low volume ejaculate were all significantly more frequent in the post-transplant patients compared to TDTM group. In the post-HSCT group, neither patients’ age at transplantation nor the conditioning regimen used in their transplant process did significantly affect their hormonal status and sperm parameters. Chronic graft versus host disease (GVHD) occurred in 14 (40%) patients. No significant difference was observed between the grade of chronic GVHD and hypogonadism (P = 0.853). Conclusions: Thalassemia patients undergone allogeneic HSCT have lower fertility potential, mainly in sperm parameters compared with patients treated with blood transfusion and chelation. This information is important for thalassemic patients considering HSCT.

11 November 2022 in Journal of Pediatric Urology
Verified
Journal Article
Closed access
TRTahereh Rostami
Tahereh Rostami
SASohrab Aghabeigi
Sohrab Aghabeigi
AKAzadeh Kiumarsi
Azadeh Kiumarsi
AKAmir Kasaeian
Amir Kasaeian
MPMehdi Kardoust Parizi
Mehdi Kardoust Parizi
SMSeied Asadollah Mousavi
Seied Asadollah Mousavi

25 March 2025 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
TRTahereh Rostami
Tahereh Rostami
MAMohammad Ahmadvand
Mohammad Ahmadvand
MAMorteza Azari
Morteza Azari
AKAmir Kasaeian
Amir Kasaeian
BCBahram Chahardouli
Bahram Chahardouli
GJGhasem Janbabai
Ghasem Janbabai
Given that natural killer (NK; CD3 − CD56 +) cells-mediated antibody-dependent cell cytotoxicity (ADCC) plays an important role in targeting neuroblastoma (NB) cells, adoptive cell therapy (ACT) utilizing expanded and activated haploidentical NK cells has emerged as a promising immunotherapeutic approach in pediatric patients with high-risk NB. In this pilot study, five pediatric patients with high-risk NB were enrolled. After harvesting hematopoietic progenitor cells (HPCs), patients received an intravenous infusion of high-activity iodine-131 (131I)-meta-iodobenzylguanidine (131I-MIBG). Seven days after the 131I-MIBG infusion and before the delivery of a single infusion of haploidentical purified NK cells, patients were administered a preparative regimen to establish a lymphodepleted host environment conducive to improved donor NK cell survival. Four days after the NK cell infusion, patients underwent the conditioning regimen, then received autologous hematopoietic stem cell transplantation (AHSCT). All patients achieved successful neutrophil and platelet engraftment. No adverse reactions were noted during or after the infusion of NK cells. Our study shows that incorporating NK cell infusion before AHSCT as a component of the conditioning regimen for consolidative therapy in pediatric patients with high-risk NB can be safe and well tolerated. IRCT Registration Number: IRCT20140818018842N32.

21 August 2024 in Iranian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
AKAzadeh Kiumarsi
Azadeh Kiumarsi
RDReza Mohamadhosseinzadeh Davatgari
Reza Mohamadhosseinzadeh Davatgari
MHMaryam Habibi
Maryam Habibi
MKMahsa Soti Khiabani
Mahsa Soti Khiabani
Introduction: Methimazole is considered the first-line antithyroid drug for Graves’ disease (GD) in children and adolescents. However, it can lead to severe adverse effects, such as agranulocytosis, which can result from direct drug toxicity or immune-mediated responses. This report aims to describe the clinical management of an adolescent with GD who developed agranulocytosis following methimazole administration. Case Presentation: A 13-year-old female, diagnosed with GD, developed neutropenia six months after starting methimazole. She was admitted with high-grade fever, sore throat, palpitations, fatigue, myalgia, and diarrhea. The treatment regimen included filgrastim, antibiotics, β-blockers, a solution of potassium iodide (SSKI), cholestyramine, and lithium. Within seven days, her absolute neutrophil count gradually improved, her fever subsided, her hyperthyroidism was controlled, and she was discharged. Discussion: Antithyroid drug-induced neutropenia represents a serious complication. In these patients, effective infection management, control of hyperthyroidism, and supportive measures to promptly increase the neutrophil count can reduce the associated morbidity and mortality. Conclusions: Close monitoring and awareness of risk factors, such as age, female sex, and higher doses of methimazole, may decrease the risk of agranulocytosis and its fatal outcomes. Alternative treatments to control hyperthyroidism during methimazole-induced agranulocytosis include β-blockade, potassium iodide solution (SSKI), cholestyramine, steroids, and lithium.